Atopic dermatitis is the most common skin disease of childhood, and its prevalence has steadily increased over the last three decades. A chronic, relapsing condition, atopic dermatitis has a significant impact on affected children, their families, and the community at large. Although the fundamental pathogenesis has remained elusive, intensive research has greatly contributed to our understanding of this disease. As the specific immunobiologic pathways become deciphered, we have seen the propagation of several new therapeutic options that rationally attack specific underlying immune system abnormalities. This article highlights the specific contributions made to the literature over the past year, with particular attention to the immunopathogenesis of atopic dermatitis, as well as some new targeted therapies currently and soon to be available.